✦ LIBER ✦

PCN38 COST-ANALYSIS OF XELOXVS. FOLFOX-4 ± BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC) IN AN ITALIAN HOSPITAL SETTING

✍ Scribed by LP Garrison; G Giuliani; P Ducournau; A Cirrincione

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN110 COST-MINIMIZATION ANALYSIS OF XEL

✍ AS Zazaa; H AlOmar; SA El-Moursy; M AlFayyadh 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

PCN26 A COST-EFFECTIVENESS ANALYSIS OF X

✍ J Darba; G Restovic; A Ramírez de Arellano 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

EC3 COST-MINIMIZATION ANALYSIS OF CAPECI

✍ G Perrocheau; M Ducreux; M Hebbar; M Ychou; G Lledo; T Conroy; R Faroux; JY Doui 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

6124 POSTER The Role of Bevacizumab (B)

✍ Moscetti, L.; Fabbri, A.; Pochesci, A.; Alesini, D.; Gemma, D.; Grande, R.; Pave 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB